1.1Probe based tumor freezing
A needle-shaped probe extracts heat from the surrounding tissue as pressurized gas expands inside its tip. Imaging tracks the ice boundary while successive freeze and thaw cycles injure cells in the target volume.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A needle-shaped probe extracts heat from the surrounding tissue as pressurized gas expands inside its tip. Imaging tracks the ice boundary while successive freeze and thaw cycles injure cells in the target volume.
A treatment planning system calculates beam angles and shapes from cross-sectional images. A rotating accelerator delivers the beams so their doses accumulate in the target, where ionization damages cellular DNA.
A cell-based assay ranks concentration-dependent changes in downstream RAS signaling. Purified-protein binding assays across several RAS isoforms then measure target engagement, and analytical measurements establish the structures of the selected compounds.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
The compound serves as a reference reagent in cultured fish cells used to study growth factor signaling. The plate contains matched wells for the compound and its solvent, and both groups receive the same growth factor stimulus. An immunoassay measures phosphorylated extracellular signal-regulated kinase in each group as a downstream readout.
A carbon-13 atom replaces a carbon-12 atom at a defined position in the compound. A carbon-13-labeled building block supplies that atom during synthesis, and the resulting molecule retains the connectivity of the unlabeled compound. Liquid chromatography coupled to high-resolution mass spectrometry distinguishes the labeled and unlabeled species by their mass difference.
A 384-well plate holds an eight-point, threefold dilution series of the compound starting at 10 micromolar. Each concentration occupies three wells, and eight additional wells receive solvent alone at the same final solvent fraction. A plate reader records the cellular signaling readout after two hours of exposure.
A microfluidic perfusion chamber holds adherent cells on an optically clear surface. An inlet valve switches between culture medium containing the compound and matching medium containing solvent alone while the pump maintains a constant flow rate. An imaging system records a fluorescent signaling reporter before exposure, during exposure, and after washout.
A surface plasmon resonance instrument carries separate flow channels with immobilized representatives of three RAS isoforms and a reference channel without immobilized protein. The instrument passes a concentration series of the compound over all channels using the same running buffer. Reference-subtracted response traces provide a record of association and dissociation for each isoform under the selected buffer and nucleotide conditions.
A liquid handler dispenses the compound and solvent controls according to a digital plate map. Software joins the plate reader output to the map by well identifier and normalizes each signal to the median solvent control signal. A four-parameter logistic fit estimates the midpoint concentration when the measured concentrations span both response plateaus.
A protonatable nitrogen in a listed structure is converted to a hydrochloride salt by treatment with hydrogen chloride. Powder diffraction identifies the crystalline form, and chloride analysis measures the counterion-to-compound ratio.
The selected compound is dissolved with a water-soluble polymer and spray dried to disperse the free base in an amorphous matrix. Powder diffraction checks for crystalline compound, and liquid chromatography measures drug loading in the dried powder.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
The structures of FTS and two preferred analogs are as follows: (i) FTS: (ii) 2-chloro-5-farnesylaminobenzoic acid (NFCB): (iii) farnesyl thionicotinic acid (FTN):A · US 2007/0054886 A1 · ¶ 46
In other words, in one embodiment of formula (II), the compound is a 12-deoxyphorbol 13-monoester. The ester may be selected from the group consisting of formate, acetate, propionate, butyrate, pentanoate, hexanoate, benzoate, and phenylacetate.B · US 2011/0224297 A1 · ¶ 51
An empty cell means only that no passage was reproduced there.
Chronic and acute neurodegeneration have been largely untreatable with previous methods.A · US 2007/0054886 A1 · ¶ 2
The inhibition of these protein kinases produces neuroprotective and neuron-treating effects as does the inhibition of the MAPK cascade.A · US 2007/0054886 A1 · ¶ 5
While these strategies are potentially promising, their in-vivo application remains limited by the fact that treatment with IL-2 or anti-CD3 causes the non-specific activation of a large number of T-cells and therefore significant toxicity.B · US 2011/0224297 A1 · ¶ 6
Because of the problems associated with currently known HIV-activating agents, there is an urgent need to investigate the effects of new compounds on the elimination of viral reservoirs.B · US 2011/0224297 A1 · ¶ 7
patent.fyi, US 2026/0355191 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355191/, SHA-256 52ad97ffaab37ba65952fbd6bd7b078d03e77fda2045f60efa0392d11c595e3f